Abstract 1409P
Background
Currently, there is still an unmet therapeutic need for patients (pts) with KRAS-mutated (mut) non-small cell lung cancer (NSCLC). Preclinical models have demonstrated the potential efficacy of the receptor activator for NF-κB ligand (RANKL) inhibitor in KRAS-mutant NSCLC. However, no clinical trials have been conducted to confirm the efficacy and safety of RANKL inhibitor combined with PD-1 inhibitors in this subset of pts.
Methods
Eligible pts had advanced KRAS-mutated NSCLC and were receiving first-line PD-1 inhibitor-based therapy. Pts were treated with PD-1 inhibitor (q3w) and denosumab (120 mg, q4w) for subsequent maintenance therapy regardless of bone metastases. The primary endpoint was progression-free survival (PFS) and the secondary endpoints were objective response rate (ORR), overall survival (OS) and safety. Biological samples were retained for exploratory analysis.
Results
As of 30 March 2023, 20 pts were recruited for maintenance therapy, of which 13 (65.0%) pts had bone metastases. The median age was 65.5 (range: 40-74) years and the majority of patients were male (75.0%). Median PFS (mPFS) for the entire treatment course (mPFS1) and maintenance therapy (mPFS2) was 329 (95% CI: 277-380) days and 196 (95% CI: 145-247) days, respectively. Median OS was not reached. The most common adverse events (AEs) were dental symptoms (20%) and hypothyroidism (10%), and one (5%) pt discontinued the treatment due to grade 2 immuno-hepatitis. No grade 3-4 AEs occurred. Subgroup analysis suggested a greater survival benefit in patients with KRAS G12C mutation than in patients with KRAS non-G12C mutation (mPFS1, p=0.026; mPFS2, p=0.049). Interestingly, patients with bone metastases (mPFS1, p=0.138; mPFS2, p=0.100) appeared to benefit more than those without. Exploratory analysis (n=14) suggested that neither baseline tissue RANKL levels nor baseline blood soluble RANKL levels were associated with the survival benefit.
Conclusions
The combination of denosumab and PD-1 inhibitors demonstrated anti-tumor activity in the advanced KRAS-mutated NSCLC with a good safety profile, which warrants further investigation.
Clinical trial identification
Chinese Clinical Trial Registry (ChiCTR2100047759).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1453P - Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Presenter: Erick Suazo Zepeda
Session: Poster session 20
1454P - Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster session 20
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1456P - Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 20
1457P - Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Presenter: Marcel Wiesweg
Session: Poster session 20
1459P - Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Presenter: Caicun Zhou
Session: Poster session 20
1460P - GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Francisco Aparisi Aparisi
Session: Poster session 20
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1463P - IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer
Presenter: Yaning Yang
Session: Poster session 20